title: Effects of 5-aminolaevulinic acid on human ovarian cancer cells and human vascular endothelial cells in vitro.
abstract: Results are reported on the cellular effects and the sensitivity of cultured tumor epithelial cells (TEC) derived from human ovarian cystadenocarcinoma and human umbilical vein-derived endothelial cells (HUVEC) to exogenous 5-aminolaevulinic acid (ALA) and ALA-induced photodynamic therapy (PDT). Cellular alterations and PDT efficiency were evaluated using colorimetric thiazolyl blue (MTT) assay, trypan blue exclusion assay, electron microscopy, and gel electrophoresis. ALA-induced protoporphyrin IX (PpIX) accumulation in TEC was associated with a concentration and time-dependent significant decrease in mitochondrial activity, increase in cell membrane permeability, and dark toxicity. Maximum PpIX loaded TEC demonstrated a high sensitivity to PDT. Neither cellular alterations nor PDT effects were observed in HUVEC under identical experimental conditions. These results indicate a potential clinical value for the use of ALA-mediated PDT to treat minimal residual disease in mucinous ovarian carcinoma. In addition, the ALA-induced PpIX cytotoxicity may be exported to a new chemotherapeutic regimen via a conventionally viewed photochemotherapeutic agent.
authors.affiliation: Department of Obstetrics and Gynecology, University of Bern, 3012, Bern, Switzerland. sspoerri@bluewin.ch
authors.forename: S
authors.initials: S
authors.lastname: Spörri
authors.forename: V
authors.initials: V
authors.lastname: Chopra
authors.forename: N
authors.initials: N
authors.lastname: Egger
authors.forename: H K
authors.initials: HK
authors.lastname: Hawkins
authors.forename: M
authors.initials: M
authors.lastname: Motamedi
authors.forename: E
authors.initials: E
authors.lastname: Dreher
authors.forename: H
authors.initials: H
authors.lastname: Schneider
mesh_terms: D000622:Aminolevulinic Acid / Q000493:pharmacokinetics / Q000633:toxicity*; D002463:Cell Membrane Permeability / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D018282:Cystadenocarcinoma, Mucinous / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000187:drug effects*; D004847:Epithelial Cells / Q000187:drug effects / Q000648:ultrastructure; D005260:Female; D006801:Humans; D007700:Kinetics; D008027:Light; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000473:pathology*; D017319:Photosensitizing Agents / Q000493:pharmacokinetics / Q000633:toxicity*; D011524:Protoporphyrins / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014471:Umbilical Veins
chemical_list: D017319:Photosensitizing Agents; D011524:Protoporphyrins; D017382:Reactive Oxygen Species; D000622:Aminolevulinic Acid; C028025:protoporphyrin IX